Literature DB >> 762741

Prazosin relieves Raynaud's vasospasm.

R Waldo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 762741

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

1.  Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension.

Authors:  T Pollare; H Lithell; I Selinus; C Berne
Journal:  Diabetologia       Date:  1988-07       Impact factor: 10.122

2.  The combined effect of prazosin and autogenic training on cold reactivity in Raynaud's phenomenon.

Authors:  R S Surwit; L M Allen; R S Gilgor; M Duvic
Journal:  Biofeedback Self Regul       Date:  1982-12

3.  Sympathetic activation after two weeks of nifedipine treatment in primary Raynaud's patients and controls.

Authors:  J Leppert; H Nilsson; U Myrdal; L Edvinsson; T Hedner; I Ringqvist
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

4.  Prazosin treatment of primary Raynaud's phenomenon.

Authors:  S L Nielsen; K Vitting; K Rasmussen
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

Review 6.  Overcoming cancer therapeutic bottleneck by drug repurposing.

Authors:  Zhe Zhang; Li Zhou; Na Xie; Edouard C Nice; Tao Zhang; Yongping Cui; Canhua Huang
Journal:  Signal Transduct Target Ther       Date:  2020-07-02

Review 7.  Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.

Authors:  Hisham F Bahmad; Timothy Demus; Maya M Moubarak; Darine Daher; Juan Carlos Alvarez Moreno; Francesca Polit; Olga Lopez; Ali Merhe; Wassim Abou-Kheir; Alan M Nieder; Robert Poppiti; Yumna Omarzai
Journal:  Med Sci (Basel)       Date:  2022-02-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.